Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

TriSalus Life Sciences (TLSI) Asset Writedowns and Impairment (2024 - 2025)

TriSalus Life Sciences has reported Asset Writedowns and Impairment over the past 2 years, most recently at $34000.0 for Q3 2025.

For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0; the TTM value through Sep 2025 reached $317000.0, changed N/A, while the annual FY2024 figure was $187000.0, N/A changed from the prior year.
Asset Writedowns and Impairment for Q3 2025 was $34000.0 at TriSalus Life Sciences, down from $57000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $187000.0 in Q4 2024 and troughed at $34000.0 in Q3 2025.